BioNTech (BNTX) PT Raised to $62 at SVB Leerink
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
BioNTech SE (BNTX) Reports Q2 Loss of $0.38
August 11, 2020 6:05 AM EDTBioNTech SE (NASDAQ: BNTX) reported Q2 EPS of ($0.38), versus ($0.24) reported last year.
Revenue: Total revenue, consisting primarily of revenue from collaboration agreements, was 41.8 million for the three months ended June 30, 2020, compared to 25.8 million for the three months ended June 30, 2019. For the period of six months ended June 30, 2020, total revenue was 69.4 million, compared to 51.9 million for the comparative prior year period. The revenue from collaboration agreements overall increased due to the recognition of revenue from our new collaboration agreements signed with Pfizer and Fosun Pharma as part of the Companys BNT162 vaccine program against... More
